Mini Review Open Access
Volume 6 | Issue 2 |
Analysis of mutational signatures in multiple cancer studies: Recent Bayesian tools
Roberta De Vito1,2, Blake Hansen2, Isabella N. Grabski3, Lorenzo Trippa4, Giovanni Parmigiani4,*
- 1Department of Biostatistics, Università la Sapienza, Roma, Italy
- 2Department of Biostatistics, Brown University School of Public Health, Providence, RI, USA
- 3New York Genome Center, New York, NY, USA
- 4Department of Data Science, Dana Farber Cancer Institute and Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA
Corresponding Author
Giovanni Parmigiani, gp@jimmy.harvard.edu
Received Date: August 04, 2025
Accepted Date: October 27, 2025
De Vito R, Hansen B, Grabski IN, Trippa L, Parmigiani G. Analysis of mutational signatures in multiple cancer studies: Recent Bayesian tools. J Cancer Biol. 2025;6(2):108-114.
Copyright: © 2025 De Vito R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
How many mutations does it take to make a uveal melanoma?
Uveal melanoma (UM) is a rare cancer that affects the choroid and, less frequently, the ciliary body or the iris (for recent reviews see [1-3]). Despite a profound knowledge of the oncogenic mechanisms behind UM tumorigenesis and despite an accurate cytogenetic and molecular prognosis, only limited advances have been made in UM therapy.
Genetic mutations in the molecular pathogenesis of gastrointestinal stromal tumor
Gastrointestinal stromal tumors are mesenchymal tumors which predominantly originate from the interstitial cells of Cajal in the intestinal lining. Around ~85% of malignant GISTs possess activating mutations in the tyrosine kinase receptors KIT or PDGFRA. The driver mutations in genes other than KIT or PDGFRA account for around 15% GISTs and belong to highly heterogeneous groups called wild-type GISTs. Around 20–40% of WT-GISTS are deficient for the succinate dehydrogenase complex (SDHA, SDHB, SDHC, SDHD).
Cancer and microenvironment: who and where is the enemy? old problem, new regards
Living cell could be considered the most sophisticated anti-entropy machinery born in the heart of the strong and ferocious pro-entropy environment of the primordial ocean full of boiling and salty water, some thirty-eight hundred million years ago on this planet. Evolution of prokaryotes with a simple cell membrane to eukaryotes and later on multi-cellular organisms, has necessitated the birth and evolution of a protective microenvironment, which could shield and secure evolution of living organisms by its sophisticated anti-entropy components
A new population screening program for BRCA mutations in Israel – Attitudes and barriers among Ashkenazi Jewish women
Israeli Jewish women of Ashkenazi ancestry have a high BRCA mutation carrier rate. Therefore, recently, Israel included free genetic testing among all Jewish women with Ashkenazi ancestry, 25 yrs. and older in its public health system. The aim of this study was to assess the intention of eligible women to be tested for BRCA mutations, and to find factors that may affect their decision.
Cancer stem cells as a biomarker – A mini review
Cancer stem cells (CSCs) also known as tumor stem cells (TSCs), are pivotal in cancer development and progression. They can be identified through specific markers and surface proteins (e.g., CD44, CD133) that differ from those on non-CSC tumor cells. As well high CSC levels often correlate with poor prognosis, aggressive disease, and resistance to conventional therapies. CSCs are more resistant to standard treatments like chemotherapy and radiation, leading to relapse and metastasis.